The convergence of artificial intelligence and ophthalmology was unmistakably the focal point of this year’s American Academy of Ophthalmology meeting in Chicago. The momentum kicked off at the Eyecelerator event, setting the stage for a deep dive into AI’s transformative potential across eye care.
FDA Director Cites Ophthalmology’s AI Leadership
AI was everywhere — from keynotes to exhibits — underscoring its undeniable role in reshaping how we diagnose, treat, and monitor ocular conditions. One of the most compelling moments was when Dr. Malvina Eydelman, MD, Director at the FDA’s Office of Ophthalmic and Ear, Nose, and Throat Devices, highlighted ophthalmology’s unique distinction: It’s still the only specialty with an FDA-cleared autonomous AI use case. This fact is a powerful testament to the pioneering role our field plays in the clinical adoption of AI.
What stood out to me was the sheer breadth of innovation. Companies showcased AI solutions tackling real-world challenges across both the diagnostic and therapeutic landscapes. From optimizing surgical workflows to addressing inefficiencies in chart documentation, the possibilities seemed boundless. It wasn’t just about what’s happening now; it was about what’s coming. Adjacent technologies, such as implantable IOP sensors and tech-enabled eyewear, are poised to accelerate AI’s integration into everyday practice, pushing the limits of how we monitor and detect diseases.
Implementing Real-World Applications in Ophthalmology
With ophthalmology being so data-rich, whether in refractive measurements for cataract surgery or retinal imaging, devices are already playing a crucial role in shaping AI’s future in this specialty. A perfect example of this is Topcon’s Harmony system, which functions as an “App Store” for AI models, enabling seamless integration of AI solutions, such as those from Toku and RetiSpec, into a device-agnostic ecosystem. This is exactly what we need for AI to thrive: interoperability and ease of use.
However, while the potential of AI is vast, the AAO meeting also brought into focus the often-overlooked barriers to adoption. These barriers — unmet clinical needs, reliability of solutions, regulatory hurdles, reimbursement pathways, and workflow integration — can make or break the implementation of even the most innovative technologies. The excitement around AI must be tempered with the understanding that any one of these factors, left unaddressed, could derail an otherwise promising technology.
At-Home OCT Seamlessly Integrates AI
Dr. Reginald Saunders, MD, a retina specialist and past president of the American Society of Retina Specialists, provided a real-world example of how to navigate these challenges. He discussed the Notal at-home OCT system, which uses AI to detect retinal fluid accumulation, offering patients with wet AMD timely interventions from the comfort of their own homes. This system not only fills a critical gap in care but also integrates seamlessly into clinical workflows while meeting regulatory and reimbursement standards. It’s a perfect illustration of how AI can drive better patient outcomes without disrupting existing systems.
As we push forward, the role of data in eye care cannot be overstated. The oft-repeated phrase “data is the new oil” feels especially relevant as health care organizations recognize the value their clinical datasets hold. Insurers, pharmaceutical companies, and other stakeholders are eager to tap into these datasets for actionable insights, which raises critical questions about data ownership. I believe that as AI continues to reshape health care, we may see the emergence of an “AI Bill of Rights” with specific provisions for data privacy and protection. Striking the right balance between innovation and patient rights will be essential.
Join Us on the AI in Eye Care Journey
AAO 2024 solidified my belief that AI will be a foundational force in the future of eye care, redefining what we even consider an “eye exam.” However, the true measure of AI’s success will not be in the technology itself but in how effectively it overcomes the systemic barriers to adoption. As we push these technological boundaries, we must remain focused on delivering tangible value to both health care providers and patients.
I’m excited to announce that my co-editor, Dr. Scot Morris, OD, and I are launching a new publication dedicated to chronicling the rapid evolution of AI in eye care. The enthusiasm we witnessed at this year’s meeting was contagious, and we’re eager to share the stories, insights, and innovations that will shape the future of AI-enabled eye care. The future is bright, and we’re excited to be part of this journey with you.
Author
